| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Purity: ≥98%
Dihydroergotamine Mesylate (DHE; Migranal) is a naturally occuring ergot alkaloid widely used to treat migraines. It functions similarly to triptans, agonistically binding to serotonin receptors and causing intracranial blood vessel vasoconstriction. However, it also interacts centrally with dopamine and adrenergic receptors.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Currently, there is no information regarding the clinical use of dihydroergotamine during lactation. Because this drug may have adverse effects on infants and reduce milk production, most authoritative bodies recommend that ergotamine be contraindicated during lactation. The manufacturer of dihydroergotamine nasal spray recommends that breastfeeding women should not breastfeed during treatment and for 3 days after the last dose. Any expressed milk during this period should be discarded. ◉ Effects on Breastfed Infants As of the revision date, no relevant published information was found. ◉ Effects on Lactation and Breast Milk As of the revision date, no relevant published information was found. |
|---|---|
| References |
|
| Additional Infomation |
Dihydroergotamine mesylate may have developmental toxicity depending on state or federal labeling requirements. Dihydroergotamine mesylate is the mesylate of dihydroergotamine, a semi-synthetic ergot alkaloid with weaker oxytocin and vasoconstrictive effects than ergotamine. Both mesylate and tartrate are used to treat migraines and orthostatic hypotension. It acts as a serotonergic agonist, non-narcotic analgesic, and vasoconstrictor. It contains dihydroergotamine. Dihydroergotamine mesylate is an ergot derivative with agonistic activity against α-adrenergic, serotonergic, and dopaminergic receptors. Dihydroergotamine mesylate likely relieves migraines by binding to and stimulating the activity of 5-HT1D receptor subtypes, thereby causing cerebral vasoconstriction. However, some studies suggest that dihydroergotamine mesylate acts on 5-HT1D receptors at the sensory nerve endings of the trigeminal nerve, thereby reducing the release of pro-inflammatory neuropeptides. It is a 9,10α-dihydro derivative of ergotamine, used as a vasoconstrictor specifically for the treatment of migraines. See also: dihydroergotamine (with the active moiety)... See more...
|
| Molecular Formula |
C34H41N5O8S
|
|---|---|
| Molecular Weight |
679.7830
|
| Exact Mass |
679.267
|
| Elemental Analysis |
C, 60.07; H, 6.08; N, 10.30; O, 18.83; S, 4.72
|
| CAS # |
6190-39-2
|
| Related CAS # |
511-12-6; 6190-39-2 (mesylate);
|
| PubChem CID |
71171
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
1001.8ºC at 760 mmHg
|
| Melting Point |
232°C
|
| Flash Point |
559.7ºC
|
| Index of Refraction |
-20 ° (C=0.25, JP Method)
|
| LogP |
2.87
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
48
|
| Complexity |
1260
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
|
| InChi Key |
ADYPXRFPBQGGAH-UMYZUSPBSA-N
|
| InChi Code |
InChI=1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23-,25-,26+,27+,32-,33+;/m1./s1
|
| Chemical Name |
(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;methanesulfonic acid
|
| Synonyms |
Dihydroergotamine Mesylate; DHE Migranal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~50 mg/mL (~73.6 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4711 mL | 7.3553 mL | 14.7106 mL | |
| 5 mM | 0.2942 mL | 1.4711 mL | 2.9421 mL | |
| 10 mM | 0.1471 mL | 0.7355 mL | 1.4711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04406649 | Completed | Drug: Dihydroergotamine | Migraine Migraine With Aura Migraine Without Aura |
Satsuma Pharmaceuticals, Inc. | September 14, 2020 | Phase 3 |
| NCT04940390 | Completed | Drug: Dihydroergotamine Drug: Placebo |
Migraine Migraine With Aura Migraine Without Aura |
Satsuma Pharmaceuticals, Inc. | June 30, 2021 | Phase 3 |
| NCT00203268 | Completed | Drug: dihydroergotamine mesylate | Migraine | Thomas Jefferson University | December 2003 | Not Applicable |
| NCT03901482 | Completed | Drug: Dihydroergotamine Drug: Placebos |
Migraine Migraine With Aura Migraine Without Aura |
Satsuma Pharmaceuticals, Inc. | June 24, 2019 | Phase 3 |
| NCT03874832 | Completed | Drug: Dihydroergotamine | Migraine Migraine With Aura Migraine Without Aura |
Satsuma Pharmaceuticals, Inc. | September 11, 2018 | Phase 1 |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
